Kim Jiman, Moon Eulsun, Kim Tae-Hun
Kyunghee-Saeng Korean Medicine Clinic, Seoul, South Korea.
Allen Clinic, Seoul, South Korea.
Explore (NY). 2018 Jul-Aug;14(4):295-299. doi: 10.1016/j.explore.2017.07.009. Epub 2018 Apr 24.
Diabetic retinopathy (DR) is one of the leading cause of blindness worldwide and the most common cause of blindness among the working population. Early treatment of the disease is essential to prevent severe visual loss among patients. But there are few therapeutic options available for early stage diabetic retinopathy. We present the case of an early stage diabetic retinopathy patient presented with retinal hemorrhages in the superior temporal area and disc hemorrhages of disc nasal area. The patient was diagnosed with mild NPDR on fundus examinations. After 6 months of taking modified-Goshaiinkigan (mGJG), the characteristic features of mild NPDR disappeared. Throughout three consecutive years of follow-ups, no evident lesions that could be diagnosed as DR were found during fundus examinations. Many components of mGJG have potential efficacy toward diabetic retinopathy. This study suggests that mGJG is a possible medication for early stage DR. Concerning the degenerative characteristics of DR, early management strategies are important in young DM patients and integrative care, such as in this case, are worth investigating further.
糖尿病性视网膜病变(DR)是全球失明的主要原因之一,也是劳动人口中失明的最常见原因。对该疾病进行早期治疗对于预防患者严重视力丧失至关重要。但早期糖尿病性视网膜病变的治疗选择很少。我们报告了一例早期糖尿病性视网膜病变患者,其颞上区域出现视网膜出血,视盘鼻侧区域出现视盘出血。经眼底检查,该患者被诊断为轻度非增殖性糖尿病性视网膜病变(NPDR)。服用改良葛根汤(mGJG)6个月后,轻度NPDR的特征消失。在连续三年的随访中,眼底检查未发现可诊断为DR的明显病变。mGJG的许多成分对糖尿病性视网膜病变具有潜在疗效。本研究表明,mGJG可能是早期DR的一种治疗药物。鉴于DR的退行性特征,早期管理策略对年轻糖尿病患者很重要,像本例这样的综合治疗值得进一步研究。